{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:27:24Z","timestamp":1790083644094,"version":"4.0.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>There are few interventional studies using CMV cell-mediated immunity (CMI) to guide antiviral prophylaxis. We assessed the Quantiferon-CMV (QTF-CMV) assay to guide CMV prophylaxis duration in high-risk organ transplant recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>\n                      A single-arm, multicenter, prospective interventional study including high-risk kidney, pancreas, liver, and heart transplant recipients who were either donor CMV-seropositive, recipient-seronegative (D\n                      <jats:sup>+<\/jats:sup>\n                      \/R\n                      <jats:sup>\u2013<\/jats:sup>\n                      ) or recipient-seropositive with antithymocyte globulin (R\n                      <jats:sup>+<\/jats:sup>\n                      \/ATG) induction. CMI testing was performed using the QTF-CMV assay at months 3, 4, 5, and 6 posttransplant. Prophylaxis was discontinued for a positive CMI but continued for a negative result up to a maximum of 6 mo. The primary endpoint was CMV viremia \u22651000 IU\/mL up to 1 y posttransplant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      One hundred eight patients were included, comprising kidney (n\u2005=\u200589), kidney-pancreas (n\u2005=\u20057), liver (n\u2005=\u200510), and heart (n\u2005=\u20052) transplants. Eighty-nine patients (82.4%) completed the study protocol (n\u2005=\u200539 D\n                      <jats:sup>+<\/jats:sup>\n                      \/R\n                      <jats:sup>\u2013<\/jats:sup>\n                      and n\u2005=\u200550 R\n                      <jats:sup>+<\/jats:sup>\n                      \/ATG). In the D\n                      <jats:sup>+<\/jats:sup>\n                      \/R\n                      <jats:sup>\u2013<\/jats:sup>\n                      group, only 1 of 39 patients (2.6%) had a positive QTF-CMV result. In the R\n                      <jats:sup>+<\/jats:sup>\n                      \/ATG group, 33 of 50 patients (66%) had a positive QTF-CMV result before 6 mo, allowing for early discontinuation of prophylaxis (28 at month 3, 4 at month 4, and 1 at month 5). During the follow-up, CMV viremia \u22651000 IU\/mL occurred in only 4 of 33 patients (12.1%) who discontinued prophylaxis early compared with 6 of 17 patients (35.3%) with negative QTF-CMV results and continued prophylaxis (hazard ratio 0.31; 95% confidence interval, 0.09-1.09;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.07). No R\n                      <jats:sup>+<\/jats:sup>\n                      patient developed CMV disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>\n                      QTF-CMV-guided prophylaxis appears useful in R\n                      <jats:sup>+<\/jats:sup>\n                      patients who may benefit from a tailored duration of prophylaxis. This strategy does not appear to be useful in D\n                      <jats:sup>+<\/jats:sup>\n                      \/R\n                      <jats:sup>\u2013<\/jats:sup>\n                      patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005173","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:01:15Z","timestamp":1724112075000},"page":"527-535","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Cell-mediated Immunity to Guide Primary Prophylaxis for CMV Infection in Organ Transplant Recipients: A Multicenter Single-arm Prospective Study"],"prefix":"10.1097","volume":"109","author":[{"given":"Javier T.","family":"Solera","sequence":"first","affiliation":[{"name":"Ajmera Transplant Center, University Health Network, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor H.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Ajmera Transplant Center, University Health Network, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cervera","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Alberta, Edmonton, AB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed M.","family":"Hosseini-Moghaddam","sequence":"additional","affiliation":[{"name":"Ajmera Transplant Center, University Health Network, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gill","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of British Columbia, Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Shalhoub","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, London Health Sciences Center, London, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Zaltzman","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Saint Michaels Hospital, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Kumar","sequence":"additional","affiliation":[{"name":"Ajmera Transplant Center, University Health Network, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Humar","sequence":"additional","affiliation":[{"name":"Ajmera Transplant Center, University Health Network, Toronto, ON, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"issue":"Suppl 4","key":"R1-20250219","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/ajt.12103","article-title":"Cytomegalovirus in solid organ transplantation.","volume":"13","author":"Razonable","year":"2013","journal-title":"Am J Transplant"},{"key":"R2-20250219","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1600-6143.2004.00382.x","article-title":"Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.","volume":"4","author":"Paya","year":"2004","journal-title":"Am J Transplant"},{"key":"R3-20250219","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1600-6143.2004.00692.x","article-title":"Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report.","volume":"5","author":"Preiksaitis","year":"2005","journal-title":"Am J Transplant"},{"key":"R4-20250219","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1600-6143.2005.01207.x","article-title":"American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation.","volume":"6","author":"Humar","year":"2006","journal-title":"Am J Transplant"},{"key":"R5-20250219","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1086\/339329","article-title":"Definitions of cytomegalovirus infection and disease in transplant recipients.","volume":"34","author":"Ljungman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R6-20250219","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/590934","article-title":"Immunocompromised hosts: Perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.","volume":"47","author":"Torres-Madriz","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"2 Suppl","key":"R7-20250219","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/01.tp.0000230459.22968.26","article-title":"Benefits of cytomegalovirus prophylaxis in solid organ transplantation.","volume":"82","author":"Pescovitz","year":"2006","journal-title":"Transplantation"},{"issue":"2 Suppl","key":"R8-20250219","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/01.tp.0000230432.39447.8b","article-title":"Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis.","volume":"82","author":"Humar","year":"2006","journal-title":"Transplantation"},{"key":"R9-20250219","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(97)05535-9","article-title":"Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].","volume":"350","author":"Gane","year":"1997","journal-title":"Lancet"},{"key":"R10-20250219","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1056\/NEJM199905133401903","article-title":"Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.","volume":"340","author":"Lowance","year":"1999","journal-title":"N Engl J Med"},{"key":"R11-20250219","doi-asserted-by":"crossref","first-page":"870","DOI":"10.7326\/0003-4819-143-12-200512200-00005","article-title":"Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.","volume":"143","author":"Kalil","year":"2005","journal-title":"Ann Intern Med"},{"key":"R12-20250219","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1086\/507337","article-title":"Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies.","volume":"43","author":"Small","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R13-20250219","doi-asserted-by":"crossref","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients\u2014Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice.","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"key":"R14-20250219","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1600-6143.2008.02191.x","article-title":"Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation.","volume":"8","author":"Mattes","year":"2008","journal-title":"Am J Transplant"},{"key":"R15-20250219","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1086\/511307","article-title":"Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease.","volume":"195","author":"La Rosa","year":"2007","journal-title":"J Infect Dis"},{"key":"R16-20250219","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1086\/314879","article-title":"Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load.","volume":"180","author":"Reusser","year":"1999","journal-title":"J Infect Dis"},{"key":"R17-20250219","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1479-5876-6-29","article-title":"Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients.","volume":"6","author":"Egli","year":"2008","journal-title":"J Transl Med"},{"key":"R18-20250219","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/j.1600-6143.2008.02294.x","article-title":"Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity.","volume":"8","author":"Westall","year":"2008","journal-title":"Am J Transplant"},{"key":"R19-20250219","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1600-6143.2009.02618.x","article-title":"Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients.","volume":"9","author":"Kumar","year":"2009","journal-title":"Am J Transplant"},{"key":"R20-20250219","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/TP.0b013e31823c1cd4","article-title":"Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia.","volume":"93","author":"Lisboa","year":"2012","journal-title":"Transplantation"},{"key":"R21-20250219","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/cid\/cis993","article-title":"Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study.","volume":"56","author":"Manuel","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R22-20250219","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/ajt.15315","article-title":"A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients.","volume":"19","author":"Kumar","year":"2019","journal-title":"Am J Transplant"},{"key":"R23-20250219","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/cid\/ciad575","article-title":"Immune monitoring-guided versus fixed duration of antiviral prophylaxis against cytomegalovirus in solid-organ transplant recipients: a multicenter, randomized clinical trial.","volume":"78","author":"Manuel","year":"2024","journal-title":"Clin Infect Dis"},{"key":"R24-20250219","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/cid\/ciab574","article-title":"Immunoguided discontinuation of prophylaxis for cytomegalovirus disease in kidney transplant recipients treated with antithymocyte globulin: a randomized clinical trial.","volume":"74","author":"P\u00e1ez-Vega","year":"2022","journal-title":"Clin Infect Dis"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T05:00:20Z","timestamp":1739941220000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000005173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005173","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]}}}